Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
European Journal of Cancer (Oxford, England : 1990)
|
October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
Marie Kostine, Eleonora Mauric, Alice Tison, et al.
Annals of the Rheumatic Diseases
|
April 12, 2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
Deanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, et al.
Journal for Immunotherapy of Cancer
|
May 28, 2026
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
Alice Tison, Deanna Jannat-Khah, Laura C Cappelli, et al.
RMD Open
|
November 29, 2023
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
Alexandra Ladouceur, Thomas Barnetche, Gael Mouterde, et al.
Rheumatology (Oxford, England)
|
December 19, 2024
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study
Alice Tison, Sandrine Jousse-Joulin, Maëlys Consigny, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 6, 2019
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison, Gilles Quéré, Laurent Misery, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
European Journal of Cancer (Oxford, England : 1990)
|
October 14, 2021
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
Marie Kostine, Eleonora Mauric, Alice Tison, et al.
Annals of the Rheumatic Diseases
|
April 12, 2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
Deanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, et al.
Journal for Immunotherapy of Cancer
|
May 28, 2026
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
Alice Tison, Deanna Jannat-Khah, Laura C Cappelli, et al.
RMD Open
|
November 29, 2023
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
Alexandra Ladouceur, Thomas Barnetche, Gael Mouterde, et al.
Rheumatology (Oxford, England)
|
December 19, 2024
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study
Alice Tison, Sandrine Jousse-Joulin, Maëlys Consigny, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
August 6, 2019
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison, Gilles Quéré, Laurent Misery, et al.
Page
of 3